Tunneling nanotubes are thin, actin-containing membrane bridges that can create direct cytoplasmic continuity between cells and permit intercellular movement of organelles and other material. In experimental systems, mesenchymal stromal/stem cells (MSCs) can form nanotube-like connections with stressed recipient cells, and mitochondria have been observed moving through these structures. Formation can be influenced by cellular stress, cytoskeletal signaling, cell-cell distance, and the experimental environment. Demonstrating a nanotube morphologically does not prove that transferred mitochondria are viable, persist, integrate into the recipient mitochondrial network, or cause functional recovery. Mechanistic claims therefore require direct tracking of organelle movement and recipient-cell consequences.
Figure 1 placeholder — Tunneling nanotubes
EV-associated transfer
EV-associated transfer refers to the possibility that extracellular vesicles or other membrane-bound particles carry mitochondrial material between cells. Reported cargo can include mitochondrial proteins, mitochondrial DNA, RNA, and in some systems mitochondrial structures or mitochondria-containing vesicular material. This category must be defined carefully because vesicle size, biogenesis, purification, and terminology vary, and larger extracellular particles can be confused with conventional small EV populations. Detection of mitochondrial molecules in an EV preparation does not establish intact-organelle transfer. Rigorous characterization should distinguish soluble contamination, nonvesicular particles, mitochondrial fragments, and genuinely vesicle-associated cargo.
Figure 2 placeholder — EV-associated transfer
Functional consequences
Functional consequences are the measurable changes that follow mitochondrial or mitochondrial-component transfer. Proposed outcomes include improved oxidative phosphorylation, ATP production, mitochondrial membrane potential, redox balance, cell survival, phagocytic function, and recovery from metabolic or ischemic stress. In some experimental models, blocking transfer pathways reduces the observed benefit, strengthening causal inference. However, transferred mitochondrial material may also act as a signal rather than as a durable energy-producing organelle. Functional interpretation should therefore distinguish metabolic rescue, signaling effects, transient complementation, and long-term mitochondrial integration.
Figure 3 placeholder — Functional consequences
Evidence limitations
Evidence limitations are substantial. Much of the mitochondrial-transfer literature is based on in-vitro systems, animal models, fluorescent labeling, microscopy, or indirect functional readouts. Mitochondrial dyes can leak or transfer independently of intact mitochondria; labels can persist after organelle damage; cell fusion, phagocytosis, extracellular debris, and imaging artifacts can mimic transfer. The frequency and clinical importance of mitochondrial transfer in humans remain uncertain, as do dose dependence, tissue specificity, persistence, immunologic consequences, and the relative contribution of nanotubes versus EV-associated or other routes. Biological plausibility should therefore remain separate from proof of therapeutic mechanism or clinical effectiveness.
Figure 4 placeholder — Evidence limitations
Clinical takeaway
Intercellular mitochondrial transfer is a plausible mechanism supported by experimental evidence, but observing mitochondrial material move between cells is not the same as proving durable mitochondrial replacement or clinical benefit.
Why stressed cells may receive mitochondria
Cell injury, oxidative stress, inflammation, and metabolic failure can alter intercellular communication. Experimental studies suggest that stressed recipient cells may generate signals that promote contact with donor cells or uptake of mitochondrial material.
Mitochondrial quality matters
A transferred mitochondrion must remain sufficiently intact and functional to contribute directly to recipient-cell metabolism. Damaged mitochondrial material may instead trigger innate immune or stress signaling.
Tracking methods
Investigators use fluorescent dyes, genetically encoded mitochondrial reporters, microscopy, flow cytometry, mitochondrial DNA variants, and other methods. Each approach has different risks of label transfer, dilution, background signal, and misidentification.
Causality
Stronger causal evidence comes from experiments that selectively disrupt the proposed transfer route and show loss of the functional effect, followed when possible by rescue or orthogonal confirmation.
Potential immune consequences
Mitochondrial DNA and other mitochondrial components can act as danger-associated molecular patterns when present in inappropriate extracellular locations. Transfer therefore cannot be assumed to be uniformly beneficial.
Product specificity
Living MSCs, conditioned media, small EV preparations, larger vesicles, and purified mitochondrial products are not interchangeable. Their mechanisms, dose units, biodistribution, manufacturing controls, and safety questions differ.
Clinical interpretation
Improved ATP, respiration, or cell survival after coculture can support a mitochondrial-transfer hypothesis but does not establish that mitochondrial transfer occurs at a therapeutically meaningful level in patients.
Knowledge gaps
Human in-vivo transfer frequency, organ distribution, persistence, recipient-cell targeting, dose-response relationships, and contribution to clinical outcomes remain incompletely defined.
Bottom-line evidence statement
Mitochondrial transfer should be treated as a specific mechanistic hypothesis requiring direct organelle tracking, route discrimination, functional causality, and human relevance—not as a generic explanation for MSC or EV effects.
Additional controlled terminology
Mitochondrial transfer is one form of intercellular transfer. A tunneling nanotube depends on the actin cytoskeleton and can create cytoplasmic continuity that permits organelle transfer from a donor cell to a recipient cell. EV-associated mechanisms may carry mitochondrial DNA or mitochondrial protein, but a mitochondrial reporter or mitochondrial dye can create label transfer artifacts. Cell fusion and phagocytosis are alternative explanations that must be excluded. Functional testing may examine oxidative phosphorylation, ATP production, mitochondrial membrane potential, metabolic rescue, transient complementation, or mitochondrial integration. Mitochondrial damage can release a danger-associated molecular pattern. Strong causal inference may require transfer blockade and orthogonal confirmation. Human in-vivo evidence remains the critical translational boundary.